Cns Pharma Antipatkonsinism

Question 1

Define Parkinsonism?

Answer 1

A progressive neurological of muscle movement disorder characterized by ms
rigidity, tremors,bradykinesia and postural instability due to loss of dopaminergic
neurons in substantia nigra resulting in imbalance of dopaminergic (inhibitory) and
cholinergic (excitatory) influences on the extrapyramidal system.

Question 2

What is Parkinsonism characterized by?

Answer 2

characterized by ms
rigidity, tremors,bradykinesia and postural instability due to loss of dopaminergic
neurons in substantia nigra resulting in imbalance of dopaminergic (inhibitory) and
cholinergic (excitatory) influences on the extrapyramidal system.

Question 3

Why is parkonsinism characterized by ms rigidity, tremors,bradykinesia and postural instability?

Answer 3

due to loss of dopaminergic
neurons in substantia nigra resulting in imbalance of dopaminergic (inhibitory) and
cholinergic (excitatory) influences on the extrapyramidal system.

Question 4

loss of dopaminergic
neurons in substantia nigra result in:

Answer 4

resulting imbalance of dopaminergic (inhibitory) and
cholinergic (excitatory) influences on the extrapyramidal system.

Question 5

Classification of antiparkinsonian drugs

Answer 5

Dopaminergic drugs:
➢Dopamine précurseurs: Levodopa (L-dopa).
➢COMT inhibitors: Tolcapone – Entacapone
➢Selective MAO-B inhibitors: Selegiline
➢Dopamine agonists: Bromocriptine
➢Release of dopamine : Amantadine
Anticholinergic drugs:
➢Synthetic atropine substitutes(M1): Benztropine –Trihexyphenidyl